Merck
  • Home
  • Search Results
  • Regenerative therapy and cancer: in vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates.

Regenerative therapy and cancer: in vitro and in vivo studies of the interaction between adipose-derived stem cells and breast cancer cells from clinical isolates.

Tissue engineering. Part A (2010-08-03)
Ludovic Zimmerlin, Albert D Donnenberg, J Peter Rubin, Per Basse, Rodney J Landreneau, Vera S Donnenberg
ABSTRACT

Adipose-derived stem cells (ASCs) have been proposed to stabilize autologous fat grafts for regenerative therapy, but their safety is unknown in the setting of reconstructive surgery after mastectomy. Both bone marrow mesenchymal stem cells (MSCs) and ASC have been shown to enhance tumorigenesis of established breast cancer cell lines, but primary patient material has not been tested. Here, we ask whether ASC promote the in vitro growth and in vivo tumorigenesis of metastatic breast cancer clinical isolates. Metastatic pleural effusion (MPE) cells were used for coculture experiments. ASC enhanced the proliferation of MPE cells in vitro (5.1-fold). For xenograft experiments (100 sorted cells/injection site), nonhematopoietic MPE cells were sorted into resting and active populations: CD90+ resting (low scatter, 2.1%≥2N DNA), CD90+ active (high scatter, 10.6%≥2N DNA), and CD90-. Resting CD90+ MPE cells were tumorigenic in 4/40 sites but growth was not augmented by ASC. Active CD90+ MPE cells were tumorigenic (17/40 sites) only when coinjected with ASC (p=0.0005, χ2 test). The multilineage potentiality and MSC-like immunophenotype of ASC were confirmed by flow cytometry, differentiation cultures, and immunostaining. The secretome profile of ASC resembled that reported for MSC, but included adipose-associated adipsin and the hormone leptin, shown to promote breast cancer growth. Our data indicate that ASC enhance the growth of active, but not resting tumor cells. Thus, reconstructive therapy utilizing ASC-augmented whole fat should be postponed until there is no evidence of active disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
3-异丁基-1-甲基黄嘌呤, ≥99% (HPLC), powder
Sigma-Aldrich
L-脯氨酸, from non-animal source, meets EP, USP testing specifications, suitable for cell culture
Sigma-Aldrich
胰岛素 人, recombinant, expressed in yeast (proprietary host)
Sigma-Aldrich
油红O, certified by the Biological Stain Commission
Sigma-Aldrich
吲哚美辛, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
L-抗坏血酸-2-磷酸三钠盐 三钠盐, ≥95.0% (HPLC)
Sigma-Aldrich
抗-肌动蛋白,α-平滑肌- FITC抗体,小鼠单克隆 小鼠抗, clone 1A4, purified from hybridoma cell culture
Sigma-Aldrich
链霉亲和素 −Cy3 来源于阿维丁链霉菌, buffered aqueous solution